View Older Stories View More Recent Stories

Feb 25, 2016 10:41AM Gilead (GILD) Announces EMA Validates MAA for Tenofovir Alafenamide in Treatment of Hepatitis B
Feb 25, 2016 10:37AM European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
Feb 24, 2016 12:17PM Gilead Sciences (GILD) Issues Preclinical Data from Investigational TLR7 in HIV Eradication; SIV DNA Reduction Noted
Feb 24, 2016 12:09PM Gilead Announces Data From New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys
Feb 23, 2016 05:00PM Gilead Sciences to Present at the RBC Capital Markets 2016 Healthcare Conference on Wednesday, February 24
Feb 23, 2016 01:04PM Gilead Sciences (GILD) Reports Results From Study to Evaluate Switching to F/TAF-Based Regimens from Truvada (F/TDF)-Based Regimens
Feb 23, 2016 12:10PM Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Regimens
Feb 22, 2016 08:31AM Gilead Launches New Grants Program to Support HIV Cure
Feb 16, 2016 08:31AM Gilead Sciences (GILD) Announces FDA Approval of Two Additional Harvoni Indications
Feb 16, 2016 08:30AM U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease
Feb 8, 2016 05:00PM Gilead Sciences to Participate in Two Upcoming Investor Conferences
Feb 2, 2016 04:01PM Gilead Sciences Announces Declaration of Q1 Cash Dividend and Increases to Shareholder Return Programs
Feb 1, 2016 05:00PM Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources
Feb 1, 2016 09:09AM Gilead Sciences (GILD) Announces EMA Validates Type II Variation Application for Truvada
Feb 1, 2016 09:02AM European Medicines Agency Validates Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Jan 29, 2016 08:17AM Gilead Sciences (GILD) Names John Milligan CEO
Jan 29, 2016 08:00AM Gilead’s John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director
Jan 26, 2016 05:00PM Gilead Sciences to Release Fourth Quarter and Full Year 2015 Financial Results on Tuesday, February 2, 2016
Jan 12, 2016 08:32AM Gilead Sciences (GILD) Announces Sumission of NDA for TAF to U.S. FDA
Jan 12, 2016 08:30AM Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
Jan 8, 2016 04:00PM Gilead Sciences to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11
Jan 5, 2016 06:01PM Gilead Sciences (GILD) Terminates Phase 2 Study of Simtuzumab in IPF
Jan 5, 2016 06:00PM Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis
Jan 5, 2016 08:33AM Gilead Sciences (GILD) Reports Two TAF Phase 3s Met Primary Objectives in Certain HBV
Jan 5, 2016 08:30AM Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
Jan 4, 2016 04:32PM Gilead Sciences (GILD) Receives FDA Priority Review for Sofosbuvir in Chronic HCV
Jan 4, 2016 04:30PM Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection
Dec 8, 2015 07:32AM Gilead Sciences (GILD) Announces Statistically Significant Results from Zydelig Combo Phase 3 in CLL
Dec 8, 2015 07:30AM Phase 3 Results for Zydelig® With Bendamustine and Rituximab for Relapsed Chronic Lymphocytic Leukemia (CLL) Presented at American Society of Hematology Annual Meeting
Nov 24, 2015 05:00PM Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, December 1
Nov 23, 2015 06:35AM European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infecti
Nov 16, 2015 09:00AM Gilead’s Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia
Nov 14, 2015 09:02AM Gilead Presents New Data at The Liver Meeting 2015
Nov 14, 2015 09:02AM Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies
Nov 12, 2015 05:54PM U.S. FDA Approves New Indications for Harvoni®, Gilead’s Once-Daily Single Tablet Regimen for Chronic Hepatitis C
Nov 9, 2015 08:30AM Gilead Sciences to Present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10
Nov 5, 2015 12:47PM U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Oct 28, 2015 05:52PM Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C
Oct 28, 2015 09:31AM Pre-Open Stock Movers 10/28: (CMI) (HOT) (CAB) (AIG) (AAPL) Higher; (MCUR) (AKAM) (ICPT) Lower (more...)
Oct 27, 2015 06:26PM After-Hours Movers 10/27: (VCRA) (NOC) (CRUS) Higher; (AKAM) (TWTR) (RAD) Lower (more...)
Oct 27, 2015 04:00PM Gilead Sciences Announces Fourth Quarter 2015 Dividend
Oct 26, 2015 02:16PM Trading Radar for 10/26: Apple (AAPL), Twitter (TWTR), Alibaba (BABA), Comcast (CMCSA), Pfizer (PFE) Report
Oct 22, 2015 07:33AM Gilead Announces Phase 3 Results for Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV
Oct 21, 2015 10:00AM Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease
Oct 20, 2015 05:00PM Gilead Sciences to Release Third Quarter 2015 Financial Results on Tuesday, October 27, 2015
Oct 2, 2015 06:19PM U.S. Food and Drug Administration Approves New Treatment Combination of Gilead’s Letairis® with Tadalafil for Pulmonary Arterial Hypertension (WHO Group 1)
Sep 25, 2015 07:33AM European CHMP Adopts Positive Opinion for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV
Sep 21, 2015 03:42PM Hillary Clinton All Bark, No Bite with Biotech Tweet
Sep 21, 2015 12:35PM Biotechs Pressured Following Clinton Tweet (IBB)
Sep 21, 2015 08:30AM Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Geno
View More Recent Stories View Older Stories